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Insulin treatment has been associated with a paradoxical worsening of diabetes retinopathy since many years in
European cohorts. Recently, this issue has been stressed by some studies conducted in other parts of the world.
However, the mechanism underlying such evolution is not well understood. An osmotic theory has been evocated but
failed to explain the clinical features of the disease. Considering recent findings from basic and clinical research, we
discuss the possibility of a synergistic hypothesis based on the simultaneous action of insulin and vascular endothelial
growth factor on eye blood vessels. We postulate that exogenous insulin could act synergistically with the vascular
endothelial growth factor expressed by ischemic retina so as to trigger vascular proliferation and the worsening of
diabetes retinopathy.
Keywords: Diabetic retinopathy, Insulin, Vascular endothelial growth factorBackground
Diabetes mellitus is a chronic disease associated with
significant morbidity and mortality owing to its multiple
micro and macrovascular complications [1, 2]. Diabetes
mellitus has reached epidemic proportions with the
greatest impact in low income countries where it re-
mains underdiagnosed, under investigated, and under-
treated [3–5]. The epidemic rise in diabetes mellitus
poses significant public health and socioeconomic chal-
lenges through diabetic complications affecting different
organs with various impact. The eye is the most com-
monly affected organ in both type 1 and type 2 diabetes.
[6]. Diabetic retinopathy is the most serious and com-
monest ocular complication associated with T2DM and
one of the leading causes of secondary blindness world-
wide [3]. Its prevalence has been reported to range from
15.3% to 42.4% in different studies [1]. Diabetic reti-
nopathy is a disease characterized by microvascular
alterations progressively leading to retinal ischemia, ret-
inal hyper-permeability, retinal neovascularization, and
macular edema. If left untreated patients with diabetic* Correspondence: noubiapjj@yahoo.fr
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countries, diabetic retinopathy constitutes the leading
cause of blindness in the working age population [8].
Different risk and progression factors for diabetic retin-
opathy have been documented and classified as modifi-
able risk factors (blood glucose, blood pressure, serum
lipids, and smoking) and non-modifiable risk factors
(duration, age, genetic predisposition, and ethnicity) [9].
However, recent literature has clearly demonstrated an
incremented risk of diabetic retinopathy with regard to
insulin treatment [1, 10–12]. Nevertheless, the mechan-
ism underlying this paradoxical association is not well
understood. Here we revisit evidence on the association
between diabetic retinopathy and insulin use, and we
propose a novel hypothesis to support this relationship.Insulin use and early worsening of diabetes
retinopathy: Paradoxical report with growing
evidence
It is established that diabetic retinopathy and related
complications are strongly associated with the presence
of chronic hyperglycemia, and results of almost all ran-
domized trials are consistent with the fact that early and
intensive glycemic control reduce both the onset and the
progression of this condition [13–20]. This tight glucosele is distributed under the terms of the Creative Commons Attribution 4.0
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to oral antidiabetic agents as reported by major trials
[19–21]. These findings along with the benefits of insu-
lin on other vascular complications support the import-
ance of tight glycemic control with insulin early in the
course of diabetes [22]. However, tight glycemic control
with insulin is associated with recurrent hypoglycemic
episodes, and the risk of early worsening of diabetic ret-
inopathy. This later has been reported in the Diabetes
Control and Complications Trial (DCCT) where this oc-
curred in 13.1% of the intensive group (using intensive
insulin therapy) versus 7.6% of the conventional treat-
ment group (using conventional insulin regime). How-
ever, this effect was reversed by 18 months, and no case
of early worsening resulted in serious visual loss [19].
Similar finding were later reported by Wang et al. in a
meta-analysis who found that the risk of diabetic retin-
opathy progression tends to increase after 6 to 12 months
of intensive therapy with insulin (odds ratio: 2.11; 95%
confidence interval: 0.54 to 8.31) compared to conven-
tional treatment. Yet, this increase in diabetic retinop-
athy risk was also reversed after 2 years of intensive
treatment with insulin. Recently, data on this paradoxical
relationship have increased, with reports from others
parts of the world [2, 11, 12]. This has been reported in
both cross-sectional and longitudinal studies [23–25].
Further evidence drawn from more recent systematic re-
view and meta-analysis support previous findings and
highlight the early worsening effect of insulin on the
progression of diabetic retinopathy [1, 10, 26].
The role of osmotic force theory: Basis and limits
In view of the difficulty in explaining the paradoxical
aggravation of diabetic retinopathy at the initiation of in-
sulin therapy, osmotic theory was proposed based on
physiological approach, and rapidly spread despite the
few available arguments to illustrate this hypothesis [27].
This theory is based on the fact that glucose is an
osmotically active molecule and can influence water
movements according to the equation: Osmolarity = 2
(Na+ + K+) + Glucose + Urea. Therefore, an important
change in glucose concentration in a given milieu can
modify the osmotic pressure and act on water retention.
To explain the early worsening of diabetic retinopathy
with intensive treatment, it has been suggested that the
rapid drop in plasma glucose concentration obtained
with intensive and aggressive glucose lowering agents
lowers the intravascular osmotic pressure. This creates
an osmotic gradient between extracellular and intravas-
cular compartment in favor of the interstitium. Water
then moves from the higher osmotic pressure level (in-
terstitium) to the lower osmotic pressure level repre-
sented here by vessels. This is more marked in the small
vessels of the eyes, which are more sensitive to waterretention. However, in spite of its logical basis, this the-
ory remains limited and cannot explain major changes
in diabetes retinopathy as well as the increase in this
paradoxical worsening of diabetic retinopathy with insu-
lin compared to oral anti-diabetic agents.
First of all, the osmotic drive force of glucose could
plausibly support the occurrence of retinal edematous
changes, but cannot explain the appearance of neo-
vessels and other retinal features associated with diabetic
retinopathy. In addition, it is worth noting that a rapid
reduction of blood glucose by up to 4 g/l will not result
to a significant change in serum osmolality than a
change in the sodium concentration by 4 mEq/l accord-
ing to the osmolarity equation mentioned above. This
suggests that the osmotic drive depends more on change
in sodium than change in glucose concentration. On the
other hand, this theory cannot explain the higher inci-
dence of diabetic retinopathy in patients on insulin ra-
ther as compared to those on oral anti-diabetic agents.
A synergistic hypothesis could explained both the
mechanism and clinical features of early
worsening of diabetes retinopathy
Previous reports on the increased incidence and worsen-
ing diabetic retinopathy with insulin compared with oral
anti-diabetic agents have led to the hypothesis that insu-
lin is probably related to the occurrence of this paradox-
ical early worsening in diabetic retinopathy with rapid
lowering of blood pressure. But the exact mechanism
underlying this report is not well understood. Here we
propose the synergistic hypothesis based on the simul-
taneous action of insulin and the vascular endothelial
growth factor (VEGF) on eye blood vessels. Our theory
is based on the fact that high dose of exogenous insulin
could act synergistically with VEGF expressed by ische-
mic retina so as to trigger vascular proliferation and
worsening of diabetic retinopathy. This explains the role
of insulin, the different clinical features found on retinal
examination, why diabetic retinopathy is more pro-
nounced in individuals with pre-existing retinal lesions
(worsening) and rare in individuals without any pre-
existing retinal abnormality. This is based on evidence
from basic science, epidemiological and interventional
diabetes therapeutic studies [2, 3, 28], and could have
important therapeutic implications.
What do we learn from basic science research on
the topic?
Insulin has been known for many years as an anabolic
hormone necessary for growth. Experiences showed that
growth hormone and insulin probably act together for
an optimal growth [28]. For instance, in rats, when the
pituitary gland and the pancreas have been removed, the
administration of growth hormone or insulin alone does
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comitant administration of growth hormone and insulin
results in an exponential growth pattern [28]. This pro-
vided evidence that insulin and growth hormone could
act synergistically probably showing that insulin is re-
quired for growth through different mechanisms. Con-
sidering that growth is dependent of blood supply, we
postulate that the role of insulin in growth implies the
formation on new vessels by increasing the expression of
VEGF. This may explain the occurrence of diabetic ret-
inopathy with new vessels in presence of insulin and not
with oral antidiabetic agents. The in vitro study of Meng
et al. supports this hypothesis by pointing out the ex-
pression of VEGF in retinal microvascular endothelial
cells as the hallmark in the pathophysiology of insulin-
associated diabetic retinopathy [29]. They showed that
insulin interacts with the NADPH oxidase subunit 4
(Nox-4) to induce excess production of reactive oxygen
species (ROS) and subsequently oxidative stress in the
retinal endothelial cells. ROS produced by insulin are in-
volved in hypoxia-inducible factor-1α (HIF-1α) activa-
tion which in turn leads to the expression of VEGF. This
latter mediates angiogenesis, neovascularization, and
blood-retinal barrier disruption allowing vascular leakage
as well [10, 29]. Considering these two findings of basic
laboratory research, it appears that insulin is necessary
for a growth to occur and is able to stimulate the growth
of new vessels. Probably the worsening of diabetic retin-
opathy attributed to insulin use might result from ROS
signaling via activation VEGF expression. This is a pos-
sible mechanism by which insulin administration can
cause neovascularization as found in diabetic retinopathy.
Evidence from epidemiological studies
Many epidemiological studies supported the fact that in-
sulin therapy is a key factor in the occurrence of early
worsening of diabetic retinopathy. To illustrate that, pa-
tients with type 1 diabetes who are almost exclusively
treated with exogenous insulin are more prone to de-
velop diabetic retinopathy after initiation of treatment as
opposed to those with type 2 diabetes. For instance, at
diagnosis of type 1 diabetes, most of patients do not
have evidence of diabetic retinopathy. But, after 15 years
of evolution and treatment of type 1 diabetes, over 90%
of patients have evidence of diabetic retinopathy [3]. In
comparison, at the diagnosis of type 2 diabetes (preclin-
ical phase of up to 12 years), up to 20% of patients have
evidence of diabetic retinopathy, and 15 years after the
diagnosis (cumulated estimate of 27 years of evolution),
only 60% of patients have evidence of diabetic retinop-
athy [3]. In addition, diabetic retinopathy is usually
worse in adolescents and young adults compared to
older individuals without any plausible explanation and
the same findings have been reported in pregnancy [9].This has long been associated with the natural course of
the disease, but the possibility of an aggravation related
to the treatment with insulin cannot be excluded. On
the other hand, puberty and young adulthood are associ-
ated with intense growth of organs probably due to a
surge of growth hormones. This hormonal surge coupled
with exogenous insulin could synergistically induce neo-
vessel formation in the eyes, based on the mechanism
explained above. Moreover, patients with type 2 diabetes
are older, are more likely to be treated with oral
hypoglycemic agents, are more likely to have other risk
factors of diabetic retinopathy, and are less likely to ex-
perience growth hormonal surge. The “synergistic effect”
is thus less pronounced in patients with type 2 diabetes
than in those with type 1 diabetes due to the less use of
exogenous insulin for glucose lowering at least at the
initiation of treatment. Despite the longer duration of
type 2 diabetes and possible associated risk factors of
diabetic retinopathy, the rate and severity of diabetic ret-
inopathy is lesser than in type 1 diabetes. This could also
explain the occurence of diabetic retinopathy found dur-
ing pregnancy in some studies.
In a recent study, we reported and discussed the wors-
ening of diabetic retinopathy observed after rapid lower-
ing of blood glucose with insulin [2]. In a group of sub-
Saharan African patients with type 2 diabetes who were
screened for diabetic retinopathy using angiography, we
observed that those treated with insulin alone had higher
rates and more severe forms of diabetic retinopathy than
those on oral agents alone [2]. This suggests that the
“synergistic effect” is more pronounced in the group on
insulin alone than in the group on oral anti-diabetic
agents alone.
Conclusions
The synergistic hypothesis appears to better explain the
occurrence and worsening of diabetic retinopathy ob-
served with the rapid lowering of blood glucose than the
long held osmotic hypothesis, which only plausibly ex-
plained the occurrence of edema. This hypothesis has po-
tential therapeutic implications as it could benefit patients
with diabetes irrespective of the type. This suggests that,
irrespective of the type of diabetes, the adjunction of an
insulin sensitizer to any patient on insulin could be bene-
ficial in terms of reduction of micro or macro-vascular
complications. The dose of insulin needed to achieve
blood glucose control will be less, thus a less pronounced
synergy of insulin and VEGF. The hypothesis however
needs to be studied in well-designed therapeutic trials.
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